Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
This online activity is designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025. Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.
Target Audience
This activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the treatment of neovascular retinal disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize emerging evidence regarding the management of nAMD
- Summarize emerging evidence regarding the management of DME
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of RVO based on clinical presentation and goals of treatment
Mark R. Barakat, MD, FASRS
Clinical Assistant Professor of Ophthalmology
University of Arizona College of Medicine
Phoenix, AZ
Director of Research
Retina Macula Institute of Arizona
Scottsdale, AZ
Medical Director
Spectra Eye Institute
Disclosures: Grant/Research Support: Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, Eyebiotech, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kanghong/Vanotech, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Perfuse, Regenxbio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology; Speakers Bureau: Alcon, Apellis, Astellas, Bausch + Lomb, Genentech, Novartis, Regeneron; Consultant: AbbVie, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, Annexon, Apellis, Arctic Vision, Astellas, Bausch + Lomb, BioCryst, Biogen, Boehringer Ingelheim, CalciMedica, Celltrion, Cencora, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, Harrow, Janssen, Neurotech, Novartis, Ocular Therapeutix, Oculis, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, Regenxbio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics; Other: NeuBase, Oxurion, RevOpsis Therapeutics.
David Eichenbaum, MD, FASRS
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL
Disclosures: Consultant, Speaker: 4DMT, AbbVie, Adverum, Akari, Amaros, ANI, Annexon, Apellis, Astellas, Bausch + Lomb, Bayer, Bitfount, Boehringer Ingelheim, Complement Therapeutics, CorEvitas/Vestrum, EcoR1, EyePoint, Genentech, Harrow, Kodiak, Kriya, Lexitas, Nanoscope, Neurotech, Notal Vision, Novartis, Ocugen, Ocular Therapeutix, Oculis, Ocuphire, Ollin, Opthea, Orasis, Outlook, Regeneron, Regenxbio, RetinAI, Revive, Roche, Samsara, Stealth, Tilak, Unity; Investigator: 4DMT, Adverum, Aerie/Alcon, Alexion, Allgenesis[KH2.1], Annexon, Astellas, Aviceda, Bayer, Boehringer Ingelheim, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Novartis, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Priovant, Regeneron, Regenxbio, RetinAI, Roche, Samsara, Stealth, Unity Equity/Stockholder/Options: 4DMT, Amaros, Boston Image Reading Center, EyePoint, Hemera, Janssen, Ollin, Revive, US Retina
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here